In agreement with this finding, inhibitors of CDC37/Hsp90, geldanamycin and witaferin A, have been found to possess anti-cancer properties by suppressing NF-κB signaling and the expression of pro-inflammatory mediators, integrins, laminins and extracellular matrix proteases [59–61]. Here, NFKB1 is linked to cancer.